Compile Data Set for Download or QSAR
Report error Found 43 Enz. Inhib. hit(s) with all data for entry = 8181
TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50: 2nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235821(US9364459, H)
Affinity DataIC50: 3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399331(CHEMBL2180882 | US9364459, C)
Affinity DataIC50: 10nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399333(CHEMBL2177142 | US9364459, D)
Affinity DataIC50: 23nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399334(CHEMBL2180878 | US9364459, B)
Affinity DataIC50: 37nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399331(CHEMBL2180882 | US9364459, C)
Affinity DataIC50: 48nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399333(CHEMBL2177142 | US9364459, D)
Affinity DataIC50: 50nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM47167(CHEMBL201511 | US8957103, Z1 | US9364459, A)
Affinity DataIC50: 90nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235820(US9364459, G)
Affinity DataIC50: 129nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399334(CHEMBL2180878 | US9364459, B)
Affinity DataIC50: 132nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235821(US9364459, H)
Affinity DataIC50: 153nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM47167(CHEMBL201511 | US8957103, Z1 | US9364459, A)
Affinity DataIC50: 166nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50309549(3-(5-Fluoro-1H-indol-3-yl)-4-(3,4,5-trimethoxyphen...)
Affinity DataIC50: 182nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235819(US9364459, F)
Affinity DataIC50: 195nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399332(CHEMBL2180881 | US9364459, E)
Affinity DataIC50: 215nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235819(US9364459, F)
Affinity DataIC50: 227nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399332(CHEMBL2180881 | US9364459, E)
Affinity DataIC50: 373nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235821(US9364459, H)
Affinity DataIC50: 554nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50: 556nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235825(US9364459, M)
Affinity DataIC50: 657nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50: 920nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235823(US9364459, K)
Affinity DataIC50: 1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235820(US9364459, G)
Affinity DataIC50: 1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235824(US9364459, L)
Affinity DataIC50: 1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235822(US9364459, J)
Affinity DataIC50: 1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM47167(CHEMBL201511 | US8957103, Z1 | US9364459, A)
Affinity DataIC50: 1.10E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235824(US9364459, L)
Affinity DataIC50: 1.21E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235824(US9364459, L)
Affinity DataIC50: 1.24E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235822(US9364459, J)
Affinity DataIC50: 1.30E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235820(US9364459, G)
Affinity DataIC50: 1.50E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399332(CHEMBL2180881 | US9364459, E)
Affinity DataIC50: 1.52E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235823(US9364459, K)
Affinity DataIC50: 1.53E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235819(US9364459, F)
Affinity DataIC50: 1.89E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399331(CHEMBL2180882 | US9364459, C)
Affinity DataIC50: 1.90E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235826(US9364459, N)
Affinity DataIC50: 2.83E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235826(US9364459, N)
Affinity DataIC50: 3.24E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235822(US9364459, J)
Affinity DataIC50: 3.58E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399333(CHEMBL2177142 | US9364459, D)
Affinity DataIC50: 6.27E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235825(US9364459, M)
Affinity DataIC50: 9.20E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235823(US9364459, K)
Affinity DataIC50: 1.00E+4nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetGlycogen synthase kinase-3 beta(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM50399334(CHEMBL2180878 | US9364459, B)
Affinity DataIC50: 1.00E+4nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235826(US9364459, N)
Affinity DataIC50: 1.00E+4nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Johannes Gutenberg-UniversitäT Mainz

US Patent
LigandPNGBDBM235825(US9364459, M)
Affinity DataIC50: 1.00E+4nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent